Sun Yat-sen University Cancer Center, Guangzhou, Guangzhou, 510060, People's Republic of China.
State Key Laboratory of Oncology in South China, Guangzhou, Guangzhou, 510060, People's Republic of China.
Cancer Med. 2023 May;12(10):11284-11292. doi: 10.1002/cam4.5838. Epub 2023 Mar 25.
Previous studies had explored the diagnostic or prognostic value of NRP-1/CD304 in blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and B-cell acute lymphoblastic leukemia (B-ALL), whereas the expression and application value of NRP-1/CD304 in other common hematological diseases have not been reported.
Bone marrow samples from 297 newly diagnosed patients with various hematological diseases were collected to detect the expression of NRP-1/CD304 by flow cytometry (FCM). The diagnostic efficacy of NRP-1/ CD304-positive diseases was analyzed by receiver operating characteristic (ROC) curve, and the area under the ROC curve (AUC) was compared.
In the research cohort, the total positive rate of NRP-1/CD304 was 14.81% (44/297), mainly distributed in BPDCN (100%, 6/6), B-ALL (48.61%, 35/72), and AML (4.48%, 3/67), with statistically significant differences (p < 0.01). Other diseases, such as T-cell acute lymphoblastic leukemia (T-ALL), B-cell non-Hodgkin lymphoma (B-NHL), T/NK-cell lymphoma and plasma cell neoplasms, did not express NRP-1/CD304. The AUC of NRP-1/CD304 was 0.936 (95% CI 0.898-0.973), 0.723 (95% CI 0.646-0.801), and 0.435 (95% CI 0.435) in BPDCN, B-ALL and AML, respectively. Besides, CD304 was commonly expressed in B-ALL with BCR-ABL1 gene rearrangement (p = 0.000), and CD304 expression was positively correlated with CD34 co-expression (p = 0.009) and CD10 co-expression (p = 0.007).
NRP-1/CD304 is only expressed in BPDCN, B-ALL and AML, but not in other common hematological diseases. This indicates that NRP-1/CD304 has no obvious diagnostic and follow-up study value in hematological diseases other than BPDCN, B-ALL, and AML.
已有研究探讨了 NRP-1/CD304 在原始神经外胚层肿瘤（BPDCN）、急性髓系白血病（AML）和 B 细胞急性淋巴细胞白血病（B-ALL）中的诊断或预后价值，然而 NRP-1/CD304 在其他常见血液系统疾病中的表达和应用价值尚未见报道。
收集 297 例新诊断的各种血液系统疾病患者的骨髓样本，采用流式细胞术（FCM）检测 NRP-1/CD304 的表达。通过受试者工作特征（ROC）曲线分析 NRP-1/CD304 阳性疾病的诊断效能，并比较 ROC 曲线下面积（AUC）。
在研究队列中，NRP-1/CD304 的总阳性率为 14.81%（44/297），主要分布于 BPDCN（100%，6/6）、B-ALL（48.61%，35/72）和 AML（4.48%，3/67），差异具有统计学意义（p<0.01）。其他疾病如 T 细胞急性淋巴细胞白血病（T-ALL）、B 细胞非霍奇金淋巴瘤（B-NHL）、T/NK 细胞淋巴瘤和浆细胞瘤均不表达 NRP-1/CD304。NRP-1/CD304 在 BPDCN、B-ALL 和 AML 中的 AUC 分别为 0.936（95%CI 0.898-0.973）、0.723（95%CI 0.646-0.801）和 0.435（95%CI 0.435）。此外，CD304 在伴有 BCR-ABL1 基因重排的 B-ALL 中普遍表达（p=0.000），CD304 的表达与 CD34 共表达呈正相关（p=0.009），与 CD10 共表达呈正相关（p=0.007）。
NRP-1/CD304 仅在 BPDCN、B-ALL 和 AML 中表达，而在其他常见血液系统疾病中不表达。这表明 NRP-1/CD304 在 BPDCN、B-ALL 和 AML 以外的血液系统疾病中，其诊断和随访研究价值不大。
